Mechanism of miR-143-3p inhibiting proliferation, migration and invasion of osteosarcoma cells by targeting MAPK7

References

• Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017;4:25–43.
   PubMed Web of Science ®Google Scholar
• Faisham WI, Mat Saad AZ, Alsaigh LN, et al. Prognostic factors and survival rate of OS: a single-institution study. Asia-Pac J Clin Oncol. 2017;13:e104–e110.
   PubMed Web of Science ®Google Scholar
• Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016;47:283–292.
   PubMed Web of Science ®Google Scholar
• Lettieri CK, Appel N, Labban N, et al. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy 2016;8:1233–1244.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kaushik G, Subramaniam D, et al. Natural compounds targeting major cell signaling pathways: a novel paradigm for OS therapy. J Hematol Oncol. 2017;10:1–13.
   PubMed Web of Science ®Google Scholar
• Kumar RR, Boro A, Fuchs B. Involvement and clinical aspects of microRNA in osteosarcoma. Int J Mol Sci. 2016;17:1–8.
   Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–222.
   PubMed Web of Science ®Google Scholar
• Sun X, Dai G, Yu L, et al. miR-143-3p inhibits the proliferation, migration and invasion in OS by targeting FOSL2. Sci Rep. 2018;8:1–10.
   PubMed Web of Science ®Google Scholar
• Kim D, Chang HR, Baek D. Rules for functional microRNA targeting. BMB Rep. 2017;50:554–559.
   PubMed Web of Science ®Google Scholar
• Lai X, Wolkenhauer O, Vera J. Understanding microRNA-mediated gene regulatory networks through mathematical modelling. Nucleic Acids Res. 2016;44:6019–6035.
   PubMed Web of Science ®Google Scholar
• Wojciechowska A, Osiak A. Katarzyna K-K. MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med. 2017;26:865–874.
   PubMed Web of Science ®Google Scholar
• Markopoulos GS, Roupakia E, Tokamani M, et al. A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr). 2017;40:303–339.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen XG, Hu X, et al. MiR-34a and miR-203 inhibit Survivin expression to control cell proliferation and survival in human osteosarcoma cells. J Cancer. 2016;7:1057–1065.
   PubMed Web of Science ®Google Scholar
• Lin W, Lin W, Wang L, et al. Analysis of miR-148b expression differences in stage-I and II parosteal osteosarcoma. Oncol Lett. 2018;16:998–1002.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Q, Niu X, et al. miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 2017;13:435–440.
   PubMed Web of Science ®Google Scholar
• Wang L, He J, Xu H, et al. MiR-143 targets CTGF and exerts tumour-suppressing functions in epithelial ovarian cancer. Am J Transl Res. 2016;8:2716–2726.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang G, Ding C, et al. Increased circular RNA UBAP2 acts as a sponge of miR-143 to promote osteosarcoma progression. Oncotarget 2017;8:61687–61697.
   PubMedGoogle Scholar
• Chen L, Yao H, Wang K, et al. Long non-coding RNA MALAT1 regulates ZEB1 expression by sponging miR-143-3p and promotes hepatocellular carcinoma progression. J Cell Biochem. 2017;118:4836–4843.
   PubMed Web of Science ®Google Scholar
• Li D, Hu J, Song H, et al. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017;9:2276–2285.
   PubMed Web of Science ®Google Scholar
• Dreas A, Mikulski M, Milik M, et al. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors. Curr Med Chem. 2017;24:3025–3053.
   PubMed Web of Science ®Google Scholar
• Acosta AM, Kadkol S. Mitogen-activated protein kinase signaling pathway in cutaneous melanoma: an updated review. Arch Pathol Lab Med. 2016;140:1290–1296.
   PubMed Web of Science ®Google Scholar
• Granados-Jaén A, Angulo-Ibáñez M, Rovira-Clavé X, et al. Absence of ERK5/MAPK7 delays tumourigenesis in Atm−/− mice. Oncotarget 2016;7:74435–74447.
   PubMedGoogle Scholar
• Gavine PR, Wang M, Yu D, et al. Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma. BMC Cancer 2015;15:454.
   PubMed Web of Science ®Google Scholar
• Tesser-Gamba F, Lopes LJ, Petrilli AS, et al. MAPK7 gene controls proliferation, migration and cell invasion in OS. Mol Carcinog. 2016;55:1700–1713.
   PubMed Web of Science ®Google Scholar